Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This study will provide chronic hepatitis C patients with low platelets (less than 75x10^9/L)
the opportunity to undergo treatment and possible cure of their virus. The main hepatitis C
drugs will be administered as standard of care, with the addition of the study drug
eltrombopag.
The investigators hypothesize that providing eltrombopag to chronic hepatitis C patients with
low platelets (less than 75x10^9/L) will permit the initiation and completion of antiviral
triple therapy with boceprevir, ribavirin, and pegylated-interferon.